Cevomed and BIAL Sign Exclusive Distribution Agreement
London, 2 October 2017 - Cevomed, the regional pharmaceutical company headquartered in Malta, and BIAL,Portuguese pharmaceutical group, have announced their new distribution agreement. Under the terms of the ten-year contract, Cevomed will be the unique distributor of BIAL’s medicines in the MENA region.
The signing of the agreement took place on Monday 2nd of October in London. Cevomed will make use of its extensive network as well as its understanding of MENA countries’ regulatory requirements to commercialize BIAL’s line of products that treat Central Nervous System (CNS) conditions in the region.
Central Nervous System disorders such as epilepsy, Parkinson’s, and depression affect a considerable number of people around the world. BIAL has invested in the research and development of medicine to treat the symptoms attributed to several CNS conditions and the agreement with Cevomed will expand the reach of their products.
Cevomed Limited (Cevomed) is a Regional pharmaceutical company headquartered in Malta with its subsidiary office in London UK.
Cevomed acts as a portal paving the way for international pharmaceutical and biotech companies striving to access the MEA healthcare market and it forms as well a link through its distinguished business model in the region between patients and evolutionary health solutions improving their quality of life.
Founded in 1924, BIAL is a Portuguese pharmaceutical group focused on researching and developing medicine and therapeutic solutions in the health area. In the recent years, Bial has been focused on quality, innovation and internationalization and has concentrated its investments in R&D of neurosciences and cardiovascular.